Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

-- -------- -------- Difference from placebo (adjusted -0.6ss. -0.8ss. mean++) (95% CI) (-0.8, (-1.0, -0.4) -0.6) ------------------------------------------- -------- -------- -------- Patients (%) achieving A1C less than7% 69 (36%) 16 (16%) 93 (41%) 41 (17%) ------------------------------------------- -------- -------- -------- FPG (mg/dL) N = 201 N = 107 N = 234 N = 247 ------------------------------------------- -------- -------- -------- Baseline (mean) 180 184 170 176 ------------------------------------------- -------- -------- -------- Change from baseline (adjusted mean++) -13 7 -12 5 ------------------------------------------- -------- -------- -------- Difference from placebo (adjusted -20ss. -17ss. mean++) (95% CI) (-31, (-24, -9) -10) ------------------------------------------- -------- -------- -------- 2-hour PPG (mg/dL) % % N = 201 N = 204 ------------------------------------------- -------- -------- -------- Baseline (mean) 257 271 ------------------------------------------- -------- -------- -------- Change from baseline (adjusted mean++) -49 -2 ------------------------------------------- -------- -------- -------- Difference from placebo (adjusted -47ss. mean++) (95% CI) (-59, -34) ------------------------------------------- -------- -------- -------- + Intent to Treat Population using last observation on study prior to metformin rescue therapy.
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/4/2015)... 4, 2015  Amgen (NASDAQ: AMGN ) will present ... a.m. ET on Thursday, May 7, 2015, at the InterContinental ... , executive vice president of Global Commercial Operations at Amgen, ... can be accessed from the Events Calendar on Amgen,s website, ... will also be available on Amgen,s website for 90 days ...
(Date:5/4/2015)... DALLAS , May 4, 2015   The ... new injection, Kybella, from internationally acclaimed plastic surgeon, ... Food and Drug Administration, is proven to reduce fat ... http://photos.prnewswire.com/prnh/20150504/213559 The active ingredient in ... and gives plastic surgeons the ability to reshape this ...
(Date:5/4/2015)... Mass. and TORONTO , ... www.generex.com ) (OTCQB:GNBT) today announced that it intends to ... it receives upon completion of a definitive licensing agreement ... Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). As ... non-binding letter of intent in respect of the licensing ...
Breaking Medicine Technology:Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... a useful and focused trial that builds on the ... best possible care for diabetic patients with chronic stable ... Society for Cardiovascular Angiography and Interventions (SCAI) encourages healthcare ... to their patients, as studied in this trial. ...
... TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 New ... 69th Scientific Sessions in New Orleans show that the investigational ... levels and provided weight loss across weekly, biweekly and monthly ... managing type 2 diabetes, a disease that affects over 250 ...
Cached Medicine Technology:SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 2SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 3SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 4Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... Charlottesville, VA (PRWEB) May 04, 2015 Ticket ... tickets at the John Paul Jones Arena in Charlottesville, ... in the history of the music business and this beloved ... down. Paul McCartney, the former member of two legendary groups: ... decades in the music business since 2013 on the “Out ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
(Date:5/4/2015)... Pricing Healthcare announces it will ... patient receiving care at St. George Surgical Center ... be performed by July 15th, 2015, and the patient must ... front and forego the filing of insurance claims). , The ... year, and it devastates more and more individuals and families. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sheltering Arms ... Center from Hale House. The Mother Hale Learning Center ... affordable Early Childhood Education. Sheltering Arms will begin operating ... to be served by the center. , Opened in ... ages six weeks to five years, many of whom ...
Breaking Medicine News(10 mins):Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2
... FRANCISCO, Calif., Oct. 5 Exelixis,Inc. (Nasdaq: EXEL ... of research and development, will present at the 2007,BIO ... (EDT) on,Wednesday, October 10, 2007. The presentation will ... page under Investors on the Exelixis website at, http://www.exelixis.com ...
... -- conference call and audio web cast on October 9, 2007 --, BELLEVILLE, ON, Oct. ... U.S. Department of Agriculture,(USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine,during ... Conference Call & Audio Web Cast ... Tuesday, October 9, 2007 ...
... creating an effective drug: finding a chemical compound that ... then delivering it to the right place in the ... support from a $478,000, five-year CAREER award from the ... part of this problem. She is creating a modular, ...
... and ASSAGO MI, Italy, Oct. 5 GENICON,and SIAD ... strategic,partnership. Under this new partnership, SIAD Healthcare S.p.A. has ... SIAD Healthcare,S.p.A. will have a position on GENICON,s Board ... of Yale University. In August of 2006, GENICON ...
... experts say , , FRIDAY, Oct. 5 (HealthDay News) -- ... to eat no more than 12 ounces of fish ... have been confused, and fish consumption has dropped. , ... by the U.S. Food and Drug Administration and the ...
... job done, study shows , FRIDAY, Oct. 5 (HealthDay News) -- ... insects, a new study reveals. , Cycads, a group of plants ... years, look similar to ferns or palms but are not related ... coniferous tress such as pines and firs. , Reporting in the ...
Cached Medicine News:Health News:Developing a modular, nanoparticle drug delivery system 2Health News:Developing a modular, nanoparticle drug delivery system 3Health News:SIAD Healthcare S.p.A. Acquires Minority Ownership in GENICON 2Health News:Fish Safe for Pregnant Women to Eat 2Health News:Fish Safe for Pregnant Women to Eat 3
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... Linear high frequency ... breast and superficial ... exclusive Hemispheric Sound ... technologies. This multi-frequency ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: